In the Spotlight: You2Yourself – Revolutionizing Early Disease Detection

The Global Health Challenge: The Cost of Late-Stage Diagnoses

Late-stage disease detection remains one of healthcare’s most significant challenges, contributing to millions of preventable deaths each year. Cancer alone claims nearly 10 million lives annually, and survival rates can plummet from over 90% when detected early to less than 20% in advanced stages. Cardiovascular disease (CVD), the world’s leading cause of death, accounts for 32% of global fatalities. By the time symptoms appear, irreversible damage has often already occurred, making early intervention critical.

In developed nations, the numbers are staggering: 27% of people aged 45 to 75 are diagnosed with cancer, and half of individuals in this group will experience cardiovascular issues by the age of 75. These conditions lead to prolonged treatments, skyrocketing healthcare costs, and declining survival rates. A shift toward early detection is vital for improving outcomes and creating a more sustainable healthcare system that can meet the needs of future generations.

A Breakthrough Solution: You2Yourself (Y2Y)

Addressing this pressing need, You2Yourself (Y2Y) was founded in 2018 by Bram de Moor and Johan de Rooij. Their groundbreaking approach is redefining healthcare by empowering individuals with proactive, personalized health insights through biomarker-based monitoring. By analyzing blood and urine samples with Next-Generation Sequencing (NGS) technology, Y2Y establishes a personal baseline of health, allowing for early detection of subtle changes that may indicate the onset of disease—often before symptoms arise.

"We started You2Yourself because we saw too many cases where diseases were diagnosed when it was already too late. We believe that no one should have to fight an advanced illness that could have been detected at an early stage. Our goal is to shift healthcare from reactive to proactive, giving people a real chance at a healthier future." — Bram de Moor, Co-Founder.

But Y2Y isn’t just stopping at biomarker analysis. The company is also pioneering AI-driven disease detection algorithms based on these individual biomarker profiles. To validate the power of this technology, You2Yourself has developed one of the most comprehensive biobanks tracking disease onset patterns. Through its Urimon study, Y2Y has collected over 200,000 blood and urine samples from more than 5,000 participants, providing unprecedented accuracy in early disease detection.

The Founders: A Visionary Partnership

Bram de Moor and Johan de Rooij’s collaboration began in 2016 when they met during their Master of Business Innovation (MBI) in Life Sciences & Health. Johan, with a background in molecular biology, had long envisioned using biomarkers to detect diseases earlier but had initially considered the idea too ambitious. Bram, bringing his legal and commercial expertise to the table, encouraged Johan to take a step-by-step approach, and together they launched You2Yourself.

Seven years later, their partnership has transformed into something truly groundbreaking. Y2Y has developed disease panels for nine different diseases, with an impressive average sensitivity of 85%. The Urimon study they started in 2019 has now grown to include over 5,000 individuals, who have collectively contributed more than 200,000 blood and urine samples. These invaluable contributions have enabled Y2Y to conduct in-depth data analysis and refine their early detection models.

Their relentless pursuit of innovation isn’t just disrupting diagnostics—it is transforming healthcare as we know it.

Expanding to the Global Market

In an effort to scale their impact, You2Yourself joined the prestigious Global Scale-Up Program (GSP) by Health-Holland. The program has provided them with vital exposure to the US healthcare system and helped refine their strategy for entering the American market. Their experience at JPM Week in San Francisco further strengthened their network, offering critical industry insights and bolstering their confidence in expanding into the US.

The pre-program in Orange County also provided essential groundwork, helping Y2Y solidify its strategy for establishing a strong presence in the US market. The message was clear: the world is ready for this paradigm shift in healthcare.

Call to Action: Join the Early Detection Movement

The time to act is now. The US healthcare market is primed for You2Yourself’s transformative solution, but to bring this cutting-edge diagnostic test to American consumers, a Urimon study must be conducted in the United States. To make this vision a reality, You2Yourself is actively seeking funding and academic partnerships.

If you are an investor, healthcare institution, or academic partner passionate about pioneering early disease detection, You2Yourself wants to connect with you. This is your opportunity to be part of a revolution that will change lives and reshape the future of healthcare.

Be Part of the Future of Healthcare

Together, we can build a system that prioritizes prevention over reaction. Join You2Yourself in making early disease detection a reality and help create a healthier, more sustainable future.

Learn More & Get Involved: 🔗 www.you2yourself.com 🔗 www.urimon.nl
Connect with the Founders: 🔗 Bram de Moor 🔗 Johan de Rooij

Let’s shape a future where diseases are caught early, lives are saved, and healthcare is truly proactive.

Written by: Mahrou Kharazi